

2023 Areas of Interest for Nemtabrutinib

Clinical:

- Unmet need for relapsed / refractory indications with no available therapy not covered by Merck/MSD clinical trials (i.e. in DLBCL, PCNS-L, cGVHD)
- Combinations with SOC, or other novel therapies (i.e CAR-T, BCL2 inhibitors, bispecifics, ADCs)
- Assess mechanisms of innate and/or acquired resistance in a clinical setting
- In CLL/SLL, early intervention for low-risk or not yet symptomatic patients

Pre-Clinical:

- Establish novel mechanisms of innate and/or acquired resistance to nemtabrutinib that occur independent or concurrent with previously described mutations.
- Evaluate hematological or non-hematological disease states beyond CLL/SLL and mantle cell lymphoma that may be susceptible to treatment with nemtabrutinib, either as a single agent or in novel combinations.
- Identify additive and or antagonistic mechanisms of action between nemtabrutinib and novel combination partners.
- Nominate biomarkers for sensitivity to single agent or combination treatment of nemtabrutinib with other available or developing treatments. Studies that clarify mechanisms by which sensitivity to nemtabrutinib is distinguished from other BTK inhibitors are of particular interest.
- Evaluate mechanisms of innate or acquired resistance to current treatments for CLL/SLL or mantle cell lymphoma that inform the appropriate use of nemtabrutinib.

Special Note: Diversity & Inclusion

We seek to foster diverse and inclusive representation within the individual Areas of Interest for each tumor type, and so encourage study concept submissions across our program which:

- Specifically focus on the outcome disparities in underrepresented populations
- Are led by non-academic programs/institutions
- Are conducted in under-represented regions or countries